Lithium's effect on bone mineral density

Bone

Volumn 44, Issue 2, 2009, Pages 331-334

  Zamani, Ali ^a,b   Omrani, Gholamhossein R ^a,b   Nasab, Masoud Mousavi ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Lithium; Osteocalcin; Osteoporosis; Urinary calcium excretion

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; LITHIUM; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GREATER TROCHANTER; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT;

ADULT; BONE DENSITY; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; LITHIUM; MALE;

EID: 58249106842     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.10.001     Document Type: Article

References (31)

1. Christiansen C., Baastrup P.C., Lindgreen P., and Transbol I. Endocrine effects of lithium. Acta Endocrinol. 88 (1978) 528-534
2. Christiansen C., Baastrup P.C., and Transbol I. Development of primary hyperparathyroidism during lithium therapy: longitudinal study. Neuropsychobiology 6 (1980) 280-283
3. Mallette L.E., and Eichhern E. Effects of lithium carbonate on human calcium metabolism. Arch. Intern. Med. 146 (1986) 770-776
4. Mallette L.E., Khouri K.H., Zengotita H., Hollis B.W., and Malini S. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J. Clin. Endocrinol. Metab. 68 (1989) 654-660
5. Nordenstrom J., Elvius M., Bagedahl-Strindlund M., Zhao B., and Torring O. Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism 43 (1994) 1563-1567
6. MAk T.W., Shek C.C., Chow C.C., Wing Y.K., and Lee S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J. Clin. Endocrinol. Metab. 83 (1998) 3857-3859
7. Lazarus J.H., Davies C.J., Woodhead J.S., Walker D.A., and Owen G.M. Effect of lithium on the metabolic response to parathyroid hormone. Mineral Electrolyte. Metab. 13 (1987) 63-66
8. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
9. Baran D.T., Schwartz M.P., Bergfeld M.A., Teitelbaum S.L., Slatopolski E., and Avioli L.V. Lithium inhibition of bone mineralization and osteoid formation. J. Clin. Invest. 61 (1978) 1691-1696
10. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., et al. Lrp 5-independent activation of Wnt signalling by lithium chloride increase bone formation and bone mass in mice. Proc. Natl. Acad. Sci. 102 (2005) 17406-17422
11. Plenge P., and Rafaelsen O.J. Lithium effects on calcium, magnesium and phosphate in man: effects on balance, bone mineral content, faecal and urinary excretion. Acta Psychiatr. Scand. 66 (1982) 361-373
12. Haden S.T., Stoll A.L., McCormick S., Scott J., and Fuleihan G.e.-H. Alterations in parathyroid dynamics in lithium-treated subjects. J. Clin. Endocrinol. Metab. 82 (1997) 2844-2848
13. Cohen O., Rais T., Lepkifker E., and Vered I. Lithium carbonate therapy is not a risk factor for osteoporosis. Horm. Metab. Res. 30 (1998) 594-597
14. Tannirandorn P., and Epstein S. Drug-induced bone loss. Osteoporos. Int. 11 (2000) 637-659
15. Portale A.A. Blood calcium, phosphorus and magnesium. In: Favus M.J., Chirstakos S., Kleerekoper M., et al. (Eds). Primer on the metabolic bone diseases and disorders of mineral metabolism (1993), Raven press, New York 87-90
16. Lemann Jr. J. Urinary excretion of calcium, magnesium and phosphorus. In: Favus M.J., Chirstakos S., Kleerekoper M., et al. (Eds). Primer on the metabolic bone diseases and disorders of mineral metabolism (1993), Raven press, New York 50-55
17. Riggs B.L., Melton III L.J., and O'Fallon W.M. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine anti fracture efficacy. Bone 18 (1996) 197S-201S
18. Melton III L.J., Khosla S., Atkinson E.J., O'fallon W.M., and Riggs B.L. Relationship of bone turnover to bone density and fractures. J. Bone Miner. Res. 12 (1997) 1083-1091
19. Greenspan S.L., Resnick N.M., and Parker R.A. Early changes in biochemical markers of bone turnover are associated with long term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 90 (2005) 2762-2767
20. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (2007) 1809-1822
21. Abugassa S., Nordenstrom J., and Jarhalt J. Bone mineral density in patients with familial hypocalciuric hypercalcemia (FHH). Eur. J. Surg. 158 (1992) 397-402
22. Law W.M., and Heath H. Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathologic studies in 21 families. Ann. Intern. Med. 102 (1985) 511-519
23. Allagui M.S., Hfaiedh N., Croute F., Guermazi F., Vincent C., Soleihavoup J.P., et al. Side effects of low serum lithium concentrations on renal, thyroid, and sexual functions in male and female rats. CR Biol. 328 (2005) 900-911
24. Cizza G., Ravn P., Chrousos G.P., and Gold P.W. Depression: a major, unrecognized risk factor for osteoprosis?. Trends Endocrinol. Metabol. 12 (2001) 198-203
25. Kinjo M., Setoguchi S., Schneeveiss S., and Solomon D.H. Bone mineral density in subjects using central nervous system active medications. Am. J. Med. 118 (2005) 1414
26. Diem S.J., Blackwell T.L., Stone K.L., Yaffe K., Haney E.M., Blizziotes M.M., et al. Use of antidepressants and rates of hip bone loss in older women: the Study of Osteoporotic Fractures. Arch. Intern. Med. 167 (2007) 1240-1245
27. Haney E.M., Chan B.K.S., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., et al. Association of low bone mineral density with selective serotonin receptor inhibitors use by older men. Arch. Intern. Med. 167 (2007) 1246-1251
28. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y.C. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90 (2005) 1294-1301
29. Armamento-Villareal R., Napoli N., Panwar V., and Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N. Eng. J. Med. 355 (2006) 2048-2050
30. Reid I.R., Candy T., Grey A.B., Horne A., Clearwater J., Anes R., et al. Addition of monfluorophosphate to osteogen therapy in postmenopausal osteoporosis a randomized controlled trials. J. Clin. Endocrinol. Metab. (2007) 2446-2452
31. Vestergaard P., Rejnmark L., and Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif. Tissue Int. 77 (2005) 1-8